PURPOSE: Primary CD30+ cutaneous lymphoproliferative disease (PCLPD) is a spectrum of indolent cutaneous T-cell lymphomas. The primary intention of the analysis of the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database was to report epidemiologic information and overall survival of patients with PCLPD. METHODS: We investigated the SEER database from 1973 to 2004 and performed univariable and multivariable survival analysis. RESULTS: A total of 268 cases of PCLPD were recorded from 1973 to 2004. Median age at diagnosis was 61 years (range, 5 to 98 years). Among cases, 58% were male, and 42% female. Race distribution was 87% white, 7% black, and 4% Asian/Pacific Islander. A total of 157 patients had primary, localized PCLPD. For the total population (N = 268), overall survival at 3 years was 81% (95% CI, 74% to 87%). Population-matched relative survival at 3 years was 87% (SE, 3.6%). Disease-specific survival at 5 years was 92% (95% CI, 86% to 95%). Head and neck skin site predicted for inferior overall survival in patients with primary, localized PCLPD on univariable analysis (hazard ratio [HR] = 4.4; P = .008; 95% CI, 1.5 to 13.2), and was suggestive of decreased overall survival on multivariate analysis (HR = 3.0; P = .06; 95% CI, 0.95 to 9.7). CONCLUSION: Localized PCLPDs are rare diseases with an excellent overall survival and occur more frequently in whites and in men. Head and neck skin primary site may be associated with poorer survival. CONCLUSIONS regarding subsets demonstrating association with survival should be taken with caution, given the small number of deaths analyzed.
PURPOSE: Primary CD30+ cutaneous lymphoproliferative disease (PCLPD) is a spectrum of indolent cutaneous T-cell lymphomas. The primary intention of the analysis of the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database was to report epidemiologic information and overall survival of patients with PCLPD. METHODS: We investigated the SEER database from 1973 to 2004 and performed univariable and multivariable survival analysis. RESULTS: A total of 268 cases of PCLPD were recorded from 1973 to 2004. Median age at diagnosis was 61 years (range, 5 to 98 years). Among cases, 58% were male, and 42% female. Race distribution was 87% white, 7% black, and 4% Asian/Pacific Islander. A total of 157 patients had primary, localized PCLPD. For the total population (N = 268), overall survival at 3 years was 81% (95% CI, 74% to 87%). Population-matched relative survival at 3 years was 87% (SE, 3.6%). Disease-specific survival at 5 years was 92% (95% CI, 86% to 95%). Head and neck skin site predicted for inferior overall survival in patients with primary, localized PCLPD on univariable analysis (hazard ratio [HR] = 4.4; P = .008; 95% CI, 1.5 to 13.2), and was suggestive of decreased overall survival on multivariate analysis (HR = 3.0; P = .06; 95% CI, 0.95 to 9.7). CONCLUSION: Localized PCLPDs are rare diseases with an excellent overall survival and occur more frequently in whites and in men. Head and neck skin primary site may be associated with poorer survival. CONCLUSIONS regarding subsets demonstrating association with survival should be taken with caution, given the small number of deaths analyzed.
Authors: Benjamin H Kaffenberger; Francisca Kartono Winardi; Julie Frederickson; Pierluigi Porcu; Henry K Wong Journal: J Clin Aesthet Dermatol Date: 2013-08
Authors: Eva Geissinger; Petra Sadler; Sabine Roth; Tina Grieb; Bernhard Puppe; Nora Müller; Peter Reimer; Claudia S Vetter-Kauczok; Jörg Wenzel; Irina Bonzheim; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Andreas Rosenwald Journal: Haematologica Date: 2010-05-29 Impact factor: 9.941
Authors: Lynn Million; Esther J Yi; Frank Wu; Rie Von Eyben; Belinda A Campbell; Bouthaina Dabaja; Richard W Tsang; Andrea Ng; Lynn D Wilson; Umberto Ricardi; Youlia Kirova; Richard T Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-24 Impact factor: 7.038
Authors: Grace L Smith; Madeleine Duvic; Zeinab Abou Yehia; Pamela Allen; Naveen Garg; Tina Suki; Sarah A Milgrom; Chelsea C Pinnix; Yasuhiro Oki; Joseph D Khoury; Bouthaina S Dabaja Journal: Adv Radiat Oncol Date: 2017-06-15